Source study found

Story checked

HIV prevention medication is highly effective, but it can complicate blood donor screening (opens in a new tab)

medicalxpress.com · 2026-11-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

2 supported
3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail

The story

HIV prevention medication is highly effective, but it can complicate blood donor screening

medicalxpress.com · 2026-11-05

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

2 supported
3 not covered

Open claim evidence

The source study

Pre-exposure prophylaxis use in blood donors in England.

Vox Sanguinis · 2026Open access

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredDaily PrEP is around 99% effective when taken correctly.View evidenceHide evidence

As statedaround 99% effective

Why this verdict

The abstract-level profile says PrEP is highly effective at preventing sexual transmission of HIV, but it does not verify the story’s specific magnitude of “around 99%,” the daily-use framing, or the condition “when taken correctly.”

Study evidence

7.1% of syphilis-positive blood samples from male blood donors tested positive for PrEP in 2023, interpreted by the authors as frequent non-compliance with blood donation eligibility criteria that exclude declared PrEP users.7.1% (proportion)

“Residual plasma samples from syphilis-positive male blood donors collected in 2023 were tested for PrEP.”

Claim 2 of 5Not coveredIf someone acquires HIV while taking PrEP, the medicine can make the infection harder to detect by lowering viral levels and delaying or weakening antibody production.View evidenceHide evidence

Why this verdict

The profile supports that PrEP use is relevant to blood donation eligibility and blood safety, but the supplied abstract-level evidence does not describe the asserted mechanism that PrEP lowers viral levels and delays or weakens antibody production after HIV acquisition. This causal/mechanistic claim may require full-text or external evidence.

Study evidence

“Residual plasma samples from syphilis-positive male blood donors collected in 2023 were tested for PrEP.”

Claim 3 of 5Not coveredAmong 84 male donors in England sampled in 2023, six samples contained both medicines used in a common PrEP tablet, and the authors say this does not prove the donors had HIV.View evidenceHide evidence

As stated84 male donors; six samples, or 7.1%

Why this verdict

The abstract-level profile supports the 2023 England male donor PrEP-detection result and the 7.1% figure, but it explicitly says the abstract does not report the sample size and does not specify which analytes/drugs were measured. Therefore the specific “84 male donors,” “six samples,” and “both medicines used in a common PrEP tablet” details are not verifiable at this depth.

Study evidence

“Residual plasma samples from syphilis-positive male blood donors collected in 2023 were tested for PrEP.”

Claim 4 of 5SupportedThe authors say their research found drugs used in PrEP in some blood donations in England, but the drugs could also have been taken for other uses and the findings do not establish HIV transmission through donated blood.View evidenceHide evidence

As statedsome blood donations; 6 samples, or 7.1%, in one tested group

Why this verdict

The paper profile supports that residual plasma from syphilis-positive male blood donors in England was tested for PrEP exposure and that 7.1% tested positive. The story’s caveats that detection does not establish why drugs were taken or prove HIV transmission are consistent with the limited observational scope, although the abstract profile does not itself elaborate the “other uses” point.

Study evidence

“Residual plasma samples from syphilis-positive male blood donors collected in 2023 were tested for PrEP.”

Claim 5 of 5SupportedThe wider analysis found that donations showing evidence of current or past syphilis increased from about four to 10 per 100,000 donations between 2018 and 2024, but this does not establish that PrEP or rule changes caused the increase.View evidenceHide evidence

As statedabout four to 10 per 100,000 donations

Why this verdict

The profile reports that syphilis-positive blood donations increased from 4.09 to 10.32 per 100,000 donations between 2018 and 2024. The story appropriately frames this as an observational trend and notes that it does not establish PrEP or rule changes as the cause.

Study evidence

The rate of syphilis-positive blood donations increased between 2018 and 2024.4.09 → 10.32 per 100,000 donations; p = 0.048 (Mann–Kendall trend test)

“These data were combined with two previous studies of syphilis-positive donors conducted between July 2018 and June 2024, incorporating demographics and reported PrEP use.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Secondary subgroup result: the proportion of past syphilis cases attributed to GBMSM increased from 18% to 37% over 2018–2024.
This is a reported abstract-level result in the paper profile, but it is not represented in the supplied story claims or caveats.
From Retrospective pooled analysis

6 things the story did carry across

Primary study aim: quantify PrEP use among syphilis-positive male blood donors in England using residual plasma testing to assess compliance with donation eligibility criteria and blood-safety implications.
Primary result: 7.1% of syphilis-positive male donor samples tested positive for PrEP exposure in 2023.
Important scope limitation: findings apply to syphilis-positive male blood donors in England and should not be generalized to all blood donors.
Interpretation limitation: PrEP detection indicates recent exposure but cannot determine exact timing, duration, or whether non-disclosure was intentional.
Secondary trend result: syphilis-positive blood donation rates increased from 4.09 to 10.32 per 100,000 donations between 2018 and 2024.
Authors’ interpretation and recommendations: PrEP positivity among syphilis-positive donors is interpreted as non-compliance with donation criteria and a need for targeted public-health and donor-education interventions, particularly around PrEP messaging and awareness of donation criteria.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

ex vivo human

1Lead resultex vivo humanQuantify PrEP use among syphilis-positive male blood donors in England (using residual plasma testing) to assess compliance with blood donation eligibility criteria and implications for blood safety.Residual plasma PrEP testing (2023 cohort)Expand

In plain English

Residual plasma samples from syphilis-positive male blood donors in England (collected in 2023) were tested for presence of PrEP drugs. 7.1% of these syphilis-positive donor samples tested positive for PrEP; the authors interpret this as frequent non-compliance with blood donation eligibility criteria that exclude declared PrEP users.

Key findings

7.1% of syphilis-positive blood samples from male blood donors tested positive for PrEP in 2023, interpreted by the authors as frequent non-compliance with blood donation eligibility criteria that exclude declared PrEP users.7.1% (proportion)

“Residual plasma samples from syphilis-positive male blood donors collected in 2023 were tested for PrEP.”

What this piece can’t prove

Detection of PrEP in plasma indicates recent exposure but cannot determine exact timing of use relative to donation or whether non-disclosure was intentional.

3 further details could not be confirmed from the summary.

2secondary dataDescribe temporal trends (2018–2024) in the rate of syphilis-positive blood donations and changes in attribution to GBMSM among past syphilis cases, using combined data from multiple studies.Retrospective pooled analysisExpand

In plain English

Pooled retrospective analysis combining a 2023 PrEP-testing dataset with two prior studies (July 2018–June 2024) found an increase in the rate of syphilis-positive blood donations and a rising share of past syphilis cases attributed to GBMSM. Specifically, the syphilis-positive donation rate rose from 4.09 to 10.32 per 100,000 donations (p = 0.048, Mann–Kendall), and the proportion of past syphilis cases attributed to GBMSM increased from 18% to 37% (p = 0.004, Fisher's; p = 0.001, Mann–Kendall). The combined dataset incorporated demographics and reported PrEP use.

Key findings

The rate of syphilis-positive blood donations increased between 2018 and 2024.4.09 → 10.32 per 100,000 donations; p = 0.048 (Mann–Kendall trend test)
The proportion of past syphilis cases attributed to GBMSM increased over 2018–2024.18% → 37%; p = 0.004 (Fisher's exact test); p = 0.001 (Mann–Kendall test)

“These data were combined with two previous studies of syphilis-positive donors conducted between July 2018 and June 2024, incorporating demographics and reported PrEP use.”

Finally, the search trail

Method layer